This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEJ0B0US_L.jpg
WASHINGTON (Reuters) – The price hike for Moderna (NASDAQ:MRNA) Inc COVID-19 shots is hard to justify, White House spokesperson Karine Jean-Pierre said on Thursday.
Moderna is considering pricing its vaccine at $110 to $130 per dose in the United States when it shifts from government contracting to commercial distribution, the company’s chief executive, Stephane Bancel, told the Wall Street Journal on Monday.
